Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $54.17 Avera

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have earned a consensus recommendation of “Buy” from the thirteen analysts that are presently covering the company, MarketBeat reports. Thirteen research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued ratings on the stock […]

Related Keywords

United States , Vickil Sato , Alexandero Schuth , , Denali Therapeutics Company Profile , Dimensional Fund Advisors , Jpmorgan Chase Co , Metlife Investment Management , Cantor Fitzgerald , Nasdaq , Denali Therapeutics Inc , Securities Exchange Commission , Blackrock Inc , Denali Therapeutics , Get Free Report , Therapeutics Trading Down , Director Vicki , Exchange Commission , Life Investment Management , Fund Advisors , Get Free , Therapeutics Inc , Denali Therapeutics Daily , Nasdaq Dnli , Dnli , Medical , Ratings , Consensus ,